News
Novo Nordisk slashes price of Ozempic
Digest more
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk (NVO) stock in focus as company decides to cut 2025 bonuses for employees in Denmark amid cost-cutting measures ...
Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month ...
Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback